R A Eeles

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. pmc Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators
    R A Eeles
    Cancer Genetics Team, ICR and Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, United Kingdom
    Am J Hum Genet 62:653-8. 1998
  2. ncbi request reprint Screening for hereditary cancer and genetic testing, epitomized by breast cancer
    R A Eeles
    Cancer Genetics Team, Institute of Cancer Research, Sutton, Surrey, U K
    Eur J Cancer 35:1954-62. 1999
  3. ncbi request reprint Chemoprevention options for BRCA1 and BRCA2 mutation carriers
    R A Eeles
    Institute of Cancer Research, The Royal Marsden National Health Service NHS Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 18:93S-9S. 2000
  4. pmc Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers
    R A Eeles
    Section of Cancer Genetics, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Breast Cancer Res 2:283-90. 2000
  5. ncbi request reprint A paradox: urgent BRCA genetic testing
    G Mitchell
    Cancer Genetics Team, The Institute of Cancer Research, Sutton, UK
    Fam Cancer 1:25-9. 2001
  6. ncbi request reprint Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
    M O Leach
    MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Lancet 365:1769-78. 2005
  7. pmc No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group
    S M Edwards
    Institute of Cancer Research, Sutton, Surrey
    Br J Cancer 76:992-1000. 1997
  8. ncbi request reprint Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer
    S Bevan
    Molecular and Population Genetics Team, Section of Cancer Genetics, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Prostate Cancer Prostatic Dis 6:12-4. 2003
  9. ncbi request reprint An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD)
    S M Edwards
    Cancer Genetics Team, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey UK
    Hum Mutat 17:220-32. 2001
  10. pmc Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group
    W D Dunsmuir
    CRC Section of Cancer Genetics and Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 78:1430-3. 1998

Detail Information

Publications30

  1. pmc Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators
    R A Eeles
    Cancer Genetics Team, ICR and Royal Marsden NHS Trust, Sutton, Surrey SM2 5PT, United Kingdom
    Am J Hum Genet 62:653-8. 1998
    ..We conclude that the HPC1 locus is responsible for only a minority of familial prostate cancer cases and that it is likely to be most important in families with at least four cases of the disease...
  2. ncbi request reprint Screening for hereditary cancer and genetic testing, epitomized by breast cancer
    R A Eeles
    Cancer Genetics Team, Institute of Cancer Research, Sutton, Surrey, U K
    Eur J Cancer 35:1954-62. 1999
    ..This proactive rather than reactive style of practising medicine is potentially exciting, however it carries with it ethical, legal and social implications for how we deal with this new knowledge...
  3. ncbi request reprint Chemoprevention options for BRCA1 and BRCA2 mutation carriers
    R A Eeles
    Institute of Cancer Research, The Royal Marsden National Health Service NHS Trust, Sutton, Surrey, United Kingdom
    J Clin Oncol 18:93S-9S. 2000
    ..There is also an increased risk of other cancers (in particular ovarian cancer and, in men, prostate cancer), and considerations regarding chemoprevention will have to encompass cancer at these sites...
  4. pmc Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers
    R A Eeles
    Section of Cancer Genetics, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Breast Cancer Res 2:283-90. 2000
    ..Carriers of BRCA1 and BRCA2 mutations are relatively rare, so the strategies for management should be determined by international multicentre studies...
  5. ncbi request reprint A paradox: urgent BRCA genetic testing
    G Mitchell
    Cancer Genetics Team, The Institute of Cancer Research, Sutton, UK
    Fam Cancer 1:25-9. 2001
    ....
  6. ncbi request reprint Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS)
    M O Leach
    MARIBS Study Office, Section of Magnetic Resonance, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey SM2 5PT, UK
    Lancet 365:1769-78. 2005
    ..Our aim was, therefore, to compare contrast enhanced magnetic resonance imaging (CE MRI) with mammography for screening...
  7. pmc No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group
    S M Edwards
    Institute of Cancer Research, Sutton, Surrey
    Br J Cancer 76:992-1000. 1997
    ..No mutations were found in these two important coding regions and we therefore conclude that MXI1 does not make a major contribution to prostate cancer susceptibility...
  8. ncbi request reprint Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer
    S Bevan
    Molecular and Population Genetics Team, Section of Cancer Genetics, Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK
    Prostate Cancer Prostatic Dis 6:12-4. 2003
    ..No pathogenic mutations in FH were identified in any of the cases. This data makes it highly unlikely that mutations in FH confer susceptibility to prostate cancer...
  9. ncbi request reprint An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD)
    S M Edwards
    Cancer Genetics Team, Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey UK
    Hum Mutat 17:220-32. 2001
    ..g. CSGE). In addition we show that this approach, which relies on band shift detection, is able to detect single base substitutions that have hitherto only been detectable by direct sequencing methods...
  10. pmc Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group
    W D Dunsmuir
    CRC Section of Cancer Genetics and Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey, UK
    Br J Cancer 78:1430-3. 1998
    ..We conclude that the incidence of allelic imbalance at HPC1 is low in both sporadic tumours and small prostate cancer families. In this group of patients, HPC1 is unlikely to be acting as a TSG in the development of prostate cancer...
  11. pmc Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
    S M Edwards
    Oncogenetics team, Section of Cancer Genetics, Institute of Cancer Research, Sutton SM2 5PT, UK
    Br J Cancer 103:918-24. 2010
    ..The germline BRCA2 mutation is associated with increased prostate cancer (PrCa) risk. We have assessed survival in young PrCa cases with a germline mutation in BRCA2 and investigated loss of heterozygosity at BRCA2 in their tumours...
  12. doi request reprint The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice
    E K Bancroft
    The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
    J Med Genet 47:486-91. 2010
    ....
  13. pmc HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease
    J C Meitz
    Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Br J Cancer 87:905-8. 2002
    ..50, 95% CI 0.79-2.85) or to patients diagnosed >55 years (OR=1.27, 95% CI 0.59-2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak...
  14. ncbi request reprint The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS)
    M O Leach
    Section of Magnetic Resonance, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK
    J Exp Clin Cancer Res 21:107-14. 2002
    ..15 cancers have been detected to date, from a total of 1236 screening measurements. This event rate and the tumour grades reported are compared with recent reports from other studies in women at high risk of breast cancer...
  15. doi request reprint Genetic variants associated with predisposition to prostate cancer and potential clinical implications
    C L Goh
    Oncogenetics team, The Institute of Cancer Research, Sutton, Surrey, UK
    J Intern Med 271:353-65. 2012
    ..International collaborations are currently underway to link genetic with clinical/epidemiological data to develop risk prediction models, which could direct screening and treatment programs...
  16. pmc CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours
    N Sodha
    Royal Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Br J Cancer 87:1445-8. 2002
    ....
  17. ncbi request reprint Genetic predisposition to cancer: the consequences of a delayed diagnosis of Gorlin syndrome
    G Mitchell
    Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK
    Clin Oncol (R Coll Radiol) 17:650-4. 2005
    ..If all relatives with cancer have died, then, at this time, genetic testing cannot usually be attempted, unless such samples have previously been stored...
  18. pmc Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript
    Z Kote-Jarai
    The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Hum Genet 129:687-94. 2011
    ..Using molecular dynamic simulation, we showed evidence that this variant has the potential to introduce alterations in the protein or affect RNA splicing. We propose that rs17632542 may directly influence PrCa risk...
  19. ncbi request reprint Cellular characteristics of nipple aspiration fluid during the menstrual cycle in healthy premenopausal women
    G Mitchell
    Section of Cancer Genetics, Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Cytopathology 12:184-96. 2001
    ....
  20. pmc Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique
    S G Jhavar
    Section of Molecular Carcinogenesis, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Clin Pathol 58:504-8. 2005
    ..To develop a method of processing non-formalin fixed prostate specimens removed at radical prostatectomy to obtain fresh tissue for research and for correlating diagnostic and molecular results with preoperative imaging...
  21. pmc ATM polymorphisms as risk factors for prostate cancer development
    S Angele
    DNA Repair Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69373 Lyon, France
    Br J Cancer 91:783-7. 2004
    ..These results provide evidence that the presence of common variants in the ATM gene, may confer an altered cellular phenotype, and that the ATM 3161C>G variant might be associated with prostate cancer risk...
  22. pmc A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
    L Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Br J Cancer 90:2002-5. 2004
    ..97; 95% CI 0.47-2.00). These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found...
  23. ncbi request reprint Apparent Mendelian inheritance of breast and colorectal cancer: chance, genetic heterogeneity or a new gene?
    L Lipton
    Cancer Research UK, Colorectal Unit, St Mark s Hospital, Harrow, UK
    Fam Cancer 1:189-95. 2001
    ..Studies such as those on APC I1307K and CHEK2 1100delC may suggest the way forward for the identification of 'breast-colon cancer' genes...
  24. pmc CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
    L Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Br J Cancer 85:36-40. 2001
    ..We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak...
  25. ncbi request reprint Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation
    A Salmon
    Sharett Institute of Oncology, Hadassah University Medical Center, 92000 Ein Kerem, Jerusalem, Israel
    Clin Oncol (R Coll Radiol) 19:490-3. 2007
    ..The aim of this study is to emphasize the importance of TP53 molecular testing in patients with very early onset breast cancer and no family history of cancer...
  26. pmc Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers
    L Kadouri
    Sharett Institute of Oncology, Hebrew University Hadassah Medical Center, Jerusalem, Israel
    Br J Cancer 98:2006-10. 2008
    ..The GSTM1- and GSTT1-null allele did not seem to have a major effect...
  27. ncbi request reprint Genotype phenotype correlation in Li-Fraumeni syndrome kindreds and its implications for management
    R N Moule
    Cancer Genetics Unit and Academic Unit of Radiotherapy, Royal Marsden NHS Foundation Trust, SW3 6JJ, London, UK
    Fam Cancer 5:129-33. 2006
  28. pmc Germline PTEN mutations in Cowden syndrome-like families
    D J Marsh
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115 6084, USA
    J Med Genet 35:881-5. 1998
    ..In addition, our data would suggest that, for the most part, the strict International Cowden Consortium operational diagnostic criteria for CS are quite robust and should remain in place...
  29. ncbi request reprint Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation
    D J Marsh
    Department of Adult Oncology and Charles A Dana Human Cancer Genetics Unit, Dana Farber Cancer Institute, Boston, MA 02115 6084, USA Molecular Oncology Laboratory, Institut Bergo
    Hum Mol Genet 7:507-15. 1998
    ..However, these observations would need to be confirmed by studying a larger number of CD families...
  30. ncbi request reprint Association between hormonal genetic polymorphisms and early-onset prostate cancer
    M S Forrest
    Cancer Research UK Cancer Medicine Research Division, University of Leeds, Leeds, UK
    Prostate Cancer Prostatic Dis 8:95-102. 2005
    ..49A >T polymorphisms and CaP risk. These findings suggest that common polymorphisms in the AR and SRD5A2 genes may be associated with early-onset CaP in British men...